The Antibiotic Drug Tigecycline: A Focus on Its Promising Anticancer Properties

Overview

Journal Front Pharmacol

Date 2016 Dec 21

PMID 27994551

Citations 22

Authors

Zhijie Xu

Yuanliang Yan

Zhi Li

Long Qian

Zhicheng Gong

Affiliations

Soon will be listed here.

Abstract

Tigecycline (TIG), the first member of glycylcycline bacteriostatic agents, has been approved to treat complicated infections in the clinic because of its expanded-spectrum antibiotic potential. Recently, an increasing number of studies have emphasized the anti-tumor effects of TIG. The inhibitory effects of TIG on cancer depend on several activating signaling pathways and abnormal mitochondrial function in cancer cells. The aim of this review is to summarize the cumulative anti-tumor evidence supporting TIG activity against different cancer types, including acute myeloid leukemia (AML), glioma, non-small cell lung cancer (NSCLC), among others. In addition, the efficacy and side effects of TIG in cancer patients are summarized in detail. Future clinical trials are also to be discussed that will evaluate the security and validate the underlying the tumor-killing properties of TIG.

Citing Articles

Ciprofloxacin-encapsulated solid lipid nanoparticles: a comprehensive biochemical analysis of cytotoxic effects, proliferation inhibition, and apoptotic induction in KG1-a leukemia cells.

Kadhim S, Dehghan G, Mahdavi M Med Oncol. 2025; 42(3):75.

PMID: 39945900 DOI: 10.1007/s12032-025-02619-2.

Third-Generation Tetracyclines: Current Knowledge and Therapeutic Potential.

Kounatidis D, Dalamaga M, Grivakou E, Karampela I, Koufopoulos P, Dalopoulos V Biomolecules. 2024; 14(7).

PMID: 39062497 PMC: 11275049. DOI: 10.3390/biom14070783.

Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery.

Bano N, Parveen S, Saeed M, Siddiqui S, Abohassan M, Mir S ACS Omega. 2024; 9(25):26762-26779.

PMID: 38947816 PMC: 11209889. DOI: 10.1021/acsomega.4c00617.

Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production.

Ramos-Acosta C, Huerta-Pantoja L, Salazar-Hidalgo M, Mayol E, Jimenez-Vega S, Garcia-Pena P Int J Mol Sci. 2024; 25(9).

PMID: 38732105 PMC: 11084384. DOI: 10.3390/ijms25094887.

Plant-derived extracts and metabolic modulation in leukemia: a promising approach to overcome treatment resistance.

Arevalo C, Cruz-Rodriguez N, Quijano S, Fiorentino S Front Mol Biosci. 2023; 10:1229760.

PMID: 37520325 PMC: 10382028. DOI: 10.3389/fmolb.2023.1229760.

References

Park S, Ozden O, Liu G, Song H, Zhu Y, Yan Y . SIRT2-Mediated Deacetylation and Tetramerization of Pyruvate Kinase Directs Glycolysis and Tumor Growth. Cancer Res. 2016; 76(13):3802-12. PMC: 4930699. DOI: 10.1158/0008-5472.CAN-15-2498. View

Norberg E, Lako A, Chen P, Stanley I, Zhou F, Ficarro S . Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 2016; 24(2):251-262. PMC: 5299709. DOI: 10.1038/cdd.2016.116. View

Secondo G, Vassallo F, Solari N, Moresco L, Percivale P, Zappi L . Empirical first-line treatment with tigecycline for febrile episodes following abdominal surgery in cancer patients. Int J Antimicrob Agents. 2010; 36(5):462-6. DOI: 10.1016/j.ijantimicag.2010.07.019. View

Reed G, Schiller G, Kambhampati S, Tallman M, Douer D, Minden M . A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med. 2016; 5(11):3031-3040. PMC: 5119957. DOI: 10.1002/cam4.845. View

Jitkova Y, Gronda M, Hurren R, Wang X, Goard C, Jhas B . A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. PLoS One. 2014; 9(5):e95281. PMC: 4037176. DOI: 10.1371/journal.pone.0095281. View

Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z . Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 2011; 20(5):674-88. PMC: 3221282. DOI: 10.1016/j.ccr.2011.10.015. View

Chen Z, Wu J, Zhang Y, Wei J, Leng X, Bi J . Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis. 2010; 10:217. PMC: 2920872. DOI: 10.1186/1471-2334-10-217. View

Bradford P, Weaver-Sands D, Petersen P . In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005; 41 Suppl 5:S315-32. DOI: 10.1086/431673. View

Alam M, Sohoni S, Kalainayakan S, Garrossian M, Zhang L . Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells. BMC Cancer. 2016; 16:150. PMC: 4766751. DOI: 10.1186/s12885-016-2200-x. View

10.

Lechman E, Gentner B, Ng S, Schoof E, van Galen P, Kennedy J . miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell. 2016; 29(2):214-28. PMC: 4749543. DOI: 10.1016/j.ccell.2015.12.011. View

11.

DAndrea A, Gritti I, Nicoli P, Giorgio M, Doni M, Conti A . The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas. Oncotarget. 2016; 7(45):72415-72430. PMC: 5341918. DOI: 10.18632/oncotarget.11719. View

12.

Joshi A, Kornfeld O, Mochly-Rosen D . The entangled ER-mitochondrial axis as a potential therapeutic strategy in neurodegeneration: A tangled duo unchained. Cell Calcium. 2016; 60(3):218-34. PMC: 5012927. DOI: 10.1016/j.ceca.2016.04.010. View

13.

Bucheit A, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D . Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014; 20(21):5527-36. PMC: 4216767. DOI: 10.1158/1078-0432.CCR-14-1027. View

14.

Averbuch D, Cordonnier C, Livermore D, Mikulska M, Orasch C, Viscoli C . Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013; 98(12):1836-47. PMC: 3856958. DOI: 10.3324/haematol.2013.091330. View

15.

Yang R, Yi L, Dong Z, Ouyang Q, Zhou J, Pang Y . Tigecycline Inhibits Glioma Growth by Regulating miRNA-199b-5p-HES1-AKT Pathway. Mol Cancer Ther. 2016; 15(3):421-9. DOI: 10.1158/1535-7163.MCT-15-0709. View

16.

Jia X, Gu Z, Chen W, Jiao J . Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function. Fundam Clin Pharmacol. 2016; 30(4):297-306. DOI: 10.1111/fcp.12199. View

17.

Li H, Jiao S, Li X, Banu H, Hamal S, Wang X . Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/β-catenin signaling. Biochem Biophys Res Commun. 2015; 467(1):14-20. DOI: 10.1016/j.bbrc.2015.09.140. View

18.

Fortin J, Mak T . Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs. Cancer Cell. 2016; 29(4):429-431. DOI: 10.1016/j.ccell.2016.03.020. View

19.

Ozdemir H, Ciftci E, Karbuz A, Oktay G, Aysev D, Yavuz G . Successful treatment of multidrug-resistant Escherichia coli bacteremia with tigecycline in an acute myeloid leukemia child. Turk J Pediatr. 2012; 54(1):59-60. View

20.

Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu N . HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Res. 2015; 76(3):572-81. PMC: 4737988. DOI: 10.1158/0008-5472.CAN-15-0671. View